114 related articles for article (PubMed ID: 1706934)
1. A bioassay for the evaluation of antiproliferative potencies of progesterone antagonists.
Michna H; Nishino Y; Schneider MR; Louton T; el Etreby MF
J Steroid Biochem Mol Biol; 1991 Mar; 38(3):359-65. PubMed ID: 1706934
[TBL] [Abstract][Full Text] [Related]
2. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death.
Michna H; Schneider MR; Nishino Y; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):447-53. PubMed ID: 2626038
[TBL] [Abstract][Full Text] [Related]
3. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.
Chwalisz K; Stöckemann K; Fritzemeier KH; Fuhrmann U
Hum Reprod Update; 1998; 4(5):570-83. PubMed ID: 10027611
[TBL] [Abstract][Full Text] [Related]
4. Progesterone antagonists block the growth of experimental mammary tumors in G0/G1.
Michna H; Schneider M; Nishino Y; el Etreby MF; McGuire WL
Breast Cancer Res Treat; 1990 Dec; 17(2):155-6. PubMed ID: 2096993
[No Abstract] [Full Text] [Related]
5. The antitumor potency of progesterone antagonists is due to their differentiation potential.
Michna H; Gehring S; Kühnel W; Nishino Y; Schneider MR
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):203-10. PubMed ID: 1525061
[TBL] [Abstract][Full Text] [Related]
6. The antiovulatory activity of progesterone antagonists is not correlated to their antiprogestational potency in the rat.
Schubert C; Donath J; Michna H; Nishino Y
J Steroid Biochem Mol Biol; 1996 Sep; 59(1):75-82. PubMed ID: 9009240
[TBL] [Abstract][Full Text] [Related]
7. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
8. Failure of two progesterone antagonists, mifepristone and onapristone, to affect luteal activity in lactating rats.
van der Schoot P; Uilenbroek JT; Slappendel EJ
J Reprod Fertil; 1989 Nov; 87(2):593-601. PubMed ID: 2513392
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat.
Schneider MR; Michna H; Nishino Y; el Etreby MF
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):691-701. PubMed ID: 2497018
[TBL] [Abstract][Full Text] [Related]
10. [Effects of progesterone antagonists on the eosinophilic granulocytes in the rat uterus].
Schubert AK
Ann Anat; 1998 Oct; 180(5):401-8. PubMed ID: 9795690
[TBL] [Abstract][Full Text] [Related]
11. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms.
Neulen J; Williams RF; Breckwoldt M; Chwalisz K; Baulieu EE; Hodgen GD
Hum Reprod; 1996 Jul; 11(7):1533-7. PubMed ID: 8671500
[TBL] [Abstract][Full Text] [Related]
12. Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats.
Stoeckemann K; Hegele-Hartung C; Chwalisz K
Hum Reprod; 1995 Dec; 10(12):3264-71. PubMed ID: 8822456
[TBL] [Abstract][Full Text] [Related]
13. Mouse bioassay for in vivo screening of oestrogen and progesterone antagonists.
Skarda J; Köhlerová E
J Vet Med A Physiol Pathol Clin Med; 2006 Apr; 53(3):145-53. PubMed ID: 16533331
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: relationship to uterine estrogen receptors.
Chwalisz K; Hegele-Hartung C; Fritzemeier KH; Beier HM; Elger W
Endocrinology; 1991 Jul; 129(1):312-22. PubMed ID: 2055191
[TBL] [Abstract][Full Text] [Related]
15. Morphology of the rat uterus after long-term treatment with progesterone antagonists.
Rumpel E; Michna H; Kühnel W
Ann Anat; 1993 Apr; 175(2):141-9. PubMed ID: 8489034
[TBL] [Abstract][Full Text] [Related]
16. Antiprogestins inhibit growth and stimulate differentiation in the normal mammary gland.
Li M; Spitzer E; Zschiesche W; Binas B; Parczyk K; Grosse R
J Cell Physiol; 1995 Jul; 164(1):1-8. PubMed ID: 7790381
[TBL] [Abstract][Full Text] [Related]
17. Modulatory actions of the new antiprogestins ZK 98.299 and ZK 98.734 and of RU 486 on luteinizing hormone secretion and progesterone effects in pituitary gonadotrophs.
Ortmann O; Hansemann K; Knuppen R; Emons G
J Steroid Biochem; 1990 Aug; 36(5):431-7. PubMed ID: 2214762
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.
Michna H; Schneider MR; Nishino Y; el Etreby MF
Breast Cancer Res Treat; 1989 Dec; 14(3):275-88. PubMed ID: 2514814
[TBL] [Abstract][Full Text] [Related]
19. Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model.
Raafat AM; Hofseth LJ; Haslam SZ
Am J Obstet Gynecol; 2001 Feb; 184(3):340-9. PubMed ID: 11228484
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice.
Nagasawa H; Aoki M; Mori T; Yamamoto K; Inaba T; Mori J
Anticancer Res; 1989; 9(4):827-32. PubMed ID: 2817809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
